WO2005018424A3 - Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits - Google Patents
Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits Download PDFInfo
- Publication number
- WO2005018424A3 WO2005018424A3 PCT/US2004/026661 US2004026661W WO2005018424A3 WO 2005018424 A3 WO2005018424 A3 WO 2005018424A3 US 2004026661 W US2004026661 W US 2004026661W WO 2005018424 A3 WO2005018424 A3 WO 2005018424A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fibrillar amyloid
- procedure
- antibodies specific
- detect
- fibrillar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Abstract
The present invention provides novel antibodies, and antibody fragments, that specifically bind to fibrillar amyloid, and not to the non-fibrillar peptide. Also provided are methods for generating, identifying, and isolating the antibodies and antibody fragments of the invention. The antibodies described herein are useful in the study, diagnosis, and treatment of Alzheimer's disease.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49615203P | 2003-08-18 | 2003-08-18 | |
US60/496,152 | 2003-08-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2005018424A2 WO2005018424A2 (en) | 2005-03-03 |
WO2005018424A3 true WO2005018424A3 (en) | 2006-04-27 |
Family
ID=34215965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/026661 WO2005018424A2 (en) | 2003-08-18 | 2004-08-18 | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2005018424A2 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8497072B2 (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9146244B2 (en) | 2007-06-12 | 2015-09-29 | Ac Immune S.A. | Polynucleotides encoding an anti-beta-amyloid monoclonal antibody |
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
US9359430B2 (en) | 2006-11-30 | 2016-06-07 | Abbvie Inc. | Abeta conformer selective anti-Abeta globulomer monoclonal antibodies |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
US9580493B2 (en) | 2011-06-23 | 2017-02-28 | Biogen International Neuroscience Gmbh | Anti-α synuclein binding molecules |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007000998A (en) | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same. |
MY148086A (en) | 2005-04-29 | 2013-02-28 | Rinat Neuroscience Corp | Antibodies directed against amyloid-beta peptide and methods using same |
AR062065A1 (en) | 2006-07-14 | 2008-10-15 | Ac Immune Sa | HUMANIZED ANTIBODY |
IL199534A (en) | 2007-01-05 | 2013-01-31 | Univ Zuerich | Isolated human antibody which is capable of selectively recognizing a neoepitope of a disorder-associated protein, a polynucleotide encoding the antibody, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, a composition comprising the antibody and methods and uses associated therewith |
AU2013204620B2 (en) * | 2007-01-05 | 2015-09-17 | University Of Zurich | Method of Providing Disease-Specific Binding Molecules and Targets |
AU2011265453B9 (en) * | 2007-01-05 | 2013-09-12 | University Of Zurich | Method of providing disease-specific binding molecules and targets |
CN103408661B (en) * | 2007-01-05 | 2016-04-06 | 苏黎世大学 | The method of disease-specific binding molecules and target is provided |
EP2486928A1 (en) | 2007-02-27 | 2012-08-15 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
ZA200905537B (en) | 2007-03-01 | 2010-10-27 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
JP5667440B2 (en) | 2007-04-18 | 2015-02-12 | プロビオドルグ エージー | Thiourea derivatives as glutaminyl cyclase inhibitors |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
EP2321348A2 (en) * | 2008-07-09 | 2011-05-18 | University of Zürich | Method of promoting neurogenesis |
EP2145898A1 (en) * | 2008-07-15 | 2010-01-20 | CHIESI FARMACEUTICI S.p.A. | Anti-amyloid immunogenic compositions, methods and uses |
PL2949666T3 (en) | 2008-12-19 | 2019-07-31 | Biogen International Neuroscience Gmbh | Human anti-alpha-synuclein antibodies |
US8512677B2 (en) | 2009-04-27 | 2013-08-20 | Case Western Reserve University | Pyro-glutamate Aβ targeting agents |
MX2012002993A (en) | 2009-09-11 | 2012-04-19 | Probiodrug Ag | Heterocylcic derivatives as inhibitors of glutaminyl cyclase. |
JP6026284B2 (en) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | Inhibitors of glutaminyl cyclase |
MX2012010470A (en) | 2010-03-10 | 2012-10-09 | Probiodrug Ag | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5). |
US8541596B2 (en) | 2010-04-21 | 2013-09-24 | Probiodrug Ag | Inhibitors |
PL3339323T3 (en) * | 2010-08-12 | 2020-05-18 | Eli Lilly And Company | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
JP6147665B2 (en) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | Amyloid beta-binding protein |
WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
DE102011057021A1 (en) | 2011-12-23 | 2013-06-27 | Forschungszentrum Jülich GmbH | Method for the selective quantification of A-beta aggregates |
CA2877516A1 (en) * | 2012-07-03 | 2014-01-03 | Janssen Alzheimer Immunotherapy | C-terminal and central epitope a-beta antibodies |
DE102013106713A1 (en) | 2013-06-26 | 2014-12-31 | Forschungszentrum Jülich GmbH | Method for identifying indicators for the determination of diseases |
MA41115A (en) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | ALZHEIMER'S DISEASE TREATMENT PROCESS |
EA202090555A1 (en) | 2017-08-22 | 2020-06-08 | Байоджен Ма Инк. | PHARMACEUTICAL COMPOSITIONS CONTAINING BETA AMYLOID ANTIBODIES |
EP3461819B1 (en) | 2017-09-29 | 2020-05-27 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
JP2023535024A (en) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | anti-Abeta antibody |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0613007A2 (en) * | 1993-02-22 | 1994-08-31 | Eli Lilly And Company | Pharmaceutical screens and antibodies |
US20030148392A1 (en) * | 1992-07-10 | 2003-08-07 | Athena Neurosciences, Inc. A Delaware Corporation | Screening compounds for the ability to alter the production of amyloid-beta peptide (x-41) |
-
2004
- 2004-08-18 WO PCT/US2004/026661 patent/WO2005018424A2/en active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030148392A1 (en) * | 1992-07-10 | 2003-08-07 | Athena Neurosciences, Inc. A Delaware Corporation | Screening compounds for the ability to alter the production of amyloid-beta peptide (x-41) |
EP0613007A2 (en) * | 1993-02-22 | 1994-08-31 | Eli Lilly And Company | Pharmaceutical screens and antibodies |
Non-Patent Citations (1)
Title |
---|
SIGURDSSON E M ET AL: "Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease associated pathology in transgenic mice.", AM J PATHOL., vol. 159, no. 2, 1 August 2001 (2001-08-01), pages 439 - 447, XP008000840 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9176150B2 (en) | 2003-01-31 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Amyloid beta(1-42) oligomers, derivatives thereof and antibodies thereto, methods of preparation thereof and use thereof |
US8497072B2 (en) | 2005-11-30 | 2013-07-30 | Abbott Laboratories | Amyloid-beta globulomer antibodies |
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
US9540432B2 (en) | 2005-11-30 | 2017-01-10 | AbbVie Deutschland GmbH & Co. KG | Anti-Aβ globulomer 7C6 antibodies |
US9359430B2 (en) | 2006-11-30 | 2016-06-07 | Abbvie Inc. | Abeta conformer selective anti-Abeta globulomer monoclonal antibodies |
US9394360B2 (en) | 2006-11-30 | 2016-07-19 | Abbvie Inc. | Aβ conformer selective anti-Aβ globulomer monoclonal antibodies |
US9146244B2 (en) | 2007-06-12 | 2015-09-29 | Ac Immune S.A. | Polynucleotides encoding an anti-beta-amyloid monoclonal antibody |
US9403902B2 (en) | 2007-10-05 | 2016-08-02 | Ac Immune S.A. | Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US9221900B2 (en) | 2010-07-30 | 2015-12-29 | Ac Immune S.A. | Methods for identifying safe and functional humanized antibodies |
US9580493B2 (en) | 2011-06-23 | 2017-02-28 | Biogen International Neuroscience Gmbh | Anti-α synuclein binding molecules |
Also Published As
Publication number | Publication date |
---|---|
WO2005018424A2 (en) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005018424A3 (en) | Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits | |
MX2007013626A (en) | Antibodies directed against amyloid-beta peptide and methods using same. | |
WO2000078344A8 (en) | Prion protein peptides and uses thereof | |
TW200617023A (en) | Antibodies directed against amyloid-beta peptide and methods using same | |
WO2005061545A3 (en) | Nogoa antibodies for the treatment of alzheimer disease | |
WO2005012493A3 (en) | Anti-cd19 antibodies | |
WO2002046222A3 (en) | Compositions and methods for diagnosing alzheimer's disease | |
WO2003068821A3 (en) | Anti-cd20 antibodies and fusion proteins thereof and methods of use | |
WO2002081505A3 (en) | Peptide for the diagnosis and therapy of alzheimer's disease | |
RS80704A (en) | ANTI- av?6.ANTIBODIES | |
AU2002237296A1 (en) | Conformationally abnormal forms of tau proteins and specific antibodies thereto | |
TW200732348A (en) | Monoclonal antibody | |
WO2003039467A3 (en) | Monoclonal antibodies specific for beta-amyloid. | |
WO2004029093A3 (en) | Humanized anti-granulocyte mn-3 antibody and uses thereof | |
EP2277917A3 (en) | B7-H3L cell surface target and a family of antibodies recognizing that target | |
WO2005028498A3 (en) | Kid3 and kid3 antibodies that bind thereto | |
WO2008034016A3 (en) | Assays for detecting native-state proteins and identifying compounds that modulate the stability of native-state proteins | |
WO2004029072A3 (en) | PrPsc -INTERACTING MOLECULES AND USES THEREOF | |
WO2004032975A3 (en) | Biphenyls and fluorenes as imaging agents in alzheimer's disease | |
HK1088909A1 (en) | Peptide-based immunization therapy for treatment of atherosclerosis | |
WO2000053742A3 (en) | Polynucleotides and proteins encoded thereby | |
WO2002046767A3 (en) | Diagnosis and treatment of alzheimer's disease | |
WO2004081199A3 (en) | Novel compositions and methods for the treatment of immune related disease | |
WO2004003155A3 (en) | Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors | |
WO2006108051A3 (en) | Compositions and methods relating to alzheimer's disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |